Abstract
Background
Carbon ion radiotherapy (CIRT) is an emerging radiation therapy to treat skull base chordomas and chondrosarcomas. To date, its use is limited to a few centers around the world, and there has been no attempt to systematically evaluate survival and toxicity outcomes reported in the literature. Correspondingly, the aim of this study was to qualitatively and quantitatively assess these outcomes.
Methods
A systematic search of seven electronic databases from inception to November 2019 was conducted following PRISMA guidelines. Articles were screened against pre-specified criteria. Outcomes were then pooled by random-effects meta-analyses of proportions.
Results
A total of nine studies provided unique metadata for assessment, with six originating from Heidelberg, Germany. The surveyed cohort size was 632 patients, with 389 (62%) chordomas and 243 (38%) chondrosarcomas of the skull base. Across all studies, median cohort age at therapy and female proportion were 46 years and 51% respectively. Estimates of local control incidence at 1-, 5-, and 10-years in chordoma-only studies were 99%, 80%, and 56%, and in chondrosarcoma-only studies were 99%, 89%, and 88%. Estimates of overall survival probability at 1-, 5-, and 10-years in chordoma-only studies were 100%, 94%, and 78%, and in chondrosarcoma-only studies were 99%, 95%, and 79%. The incidence of early and late toxicity (Grade ≥ 3) ranged from 0 to 4% across all study groups.
Conclusions
The emerging use of CIRT to treat skull base chordomas and chondrosarcomas appear promising with regard to tumor control, overall survival, and risk profile of early and late toxicity. The current literature suffers from the fact only a few centers in the world currently employ this technology.
Similar content being viewed by others
References
Volpe NJ, Liebsch NJ, Munzenrider JE, Lessell S (1993) Neuro-ophthalmologic findings in chordoma and chondrosarcoma of the skull base. Am J Ophthalmol 115(1):97–104. https://doi.org/10.1016/s0002-9394(14)73531-7
Smoll NR, Gautschi OP, Radovanovic I, Schaller K, Weber DC (2013) Incidence and relative survival of chordomas: the standardized mortality ratio and the impact of chordomas on a population. Cancer 119(11):2029–2037. https://doi.org/10.1002/cncr.28032
Heffelfinger MJ, Dahlin DC, MacCarty CS, Beabout JW (1973) Chordomas and cartilaginous tumors at the skull base. Cancer 32(2):410–420
Giuffrida AY, Burgueno JE, Koniaris LG, Gutierrez JC, Duncan R, Scully SP (2009) Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. J Bone Joint Surg Am 91(5):1063–1072. https://doi.org/10.2106/JBJS.H.00416
Bloch OG, Jian BJ, Yang I, Han SJ, Aranda D, Ahn BJ, Parsa AT (2009) A systematic review of intracranial chondrosarcoma and survival. J Clin Neurosci 16(12):1547–1551. https://doi.org/10.1016/j.jocn.2009.05.003
Fernandez-Miranda JC, Gardner PA, Snyderman CH, Devaney KO, Mendenhall WM, Suárez C, Rinaldo A, Ferlito A (2014) Clival chordomas: a pathological, surgical, and radiotherapeutic review. Head Neck 36(6):892–906. https://doi.org/10.1002/hed.23415
McDonald MW, Linton OR, Moore MG, Ting JY, Cohen-Gadol AA, Shah MV (2016) Influence of residual tumor volume and radiation dose coverage in outcomes for clival chordoma. Int J Radiat Oncol Biol Phys 95(1):304–311. https://doi.org/10.1016/j.ijrobp.2015.08.011
Potluri S, Jefferies SJ, Jena R, Harris F, Burton KE, Prevost AT, Burnet NG (2011) Residual postoperative tumour volume predicts outcome after high-dose radiotherapy for chordoma and chondrosarcoma of the skull base and spine. Clin Oncol (R Coll Radiol) 23(3):199–208. https://doi.org/10.1016/j.clon.2010.09.011
Noël G, Feuvret L, Ferrand R, Boisserie G, Mazeron J-J, Habrand J-L (2004) Radiotherapeutic factors in the management of cervical-basal chordomas and chondrosarcomas. Neurosurgery 55(6):1252–1262. https://doi.org/10.1227/01.neu.0000143330.30405.aa
Schulz-Ertner D, Haberer T, Jakel O, Thilmann C, Kramer M, Enghardt W, Kraft G, Wannenmacher M, Debus J (2002) Radiotherapy for chordomas and low-grade chondrosarcomas of the skull base with carbon ions. Int J Radiat Oncol Biol Phys 53(1):36–42
Debus J, Hug EB, Liebsch NJ, O'Farrel D, Finkelstein D, Efird J, Munzenrider JE (1997) Brainstem tolerance to conformal radiotherapy of skull base tumors. Int J Radiat Oncol Biol Phys 39(5):967–975. https://doi.org/10.1016/s0360-3016(97)00364-7
Leeman JE, Romesser PB, Zhou Y, McBride S, Riaz N, Sherman E, Cohen MA, Cahlon O, Lee N (2017) Proton therapy for head and neck cancer: expanding the therapeutic window. Lancet Oncol 18(5):e254–e265. https://doi.org/10.1016/S1470-2045(17)30179-1
Amichetti M, Amelio D, Cianchetti M, Enrici RM, Minniti G (2010) A systematic review of proton therapy in the treatment of chondrosarcoma of the skull base. Neurosurg Rev 33(2):155–165. https://doi.org/10.1007/s10143-009-0235-z
Hu M, Jiang L, Cui X, Zhang J, Yu J (2018) Proton beam therapy for cancer in the era of precision medicine. J Hematol Oncol 11(1):136. https://doi.org/10.1186/s13045-018-0683-4
Palm A, Johansson KA (2007) A review of the impact of photon and proton external beam radiotherapy treatment modalities on the dose distribution in field and out-of-field; implications for the long-term morbidity of cancer survivors. Acta Oncol 46(4):462–473. https://doi.org/10.1080/02841860701218626
Kraft G (1999) RBE and its interpretation. Strahlenther Onkol 175(Suppl 2):44–47. https://doi.org/10.1007/bf03038887
Schulz-Ertner D, Haberer T, Jäkel O, Thilmann C, Krämer M, Enghardt W, Kraft G, Wannenmacher M, Debus J (2002) Radiotherapy for chordomas and low-grade chondrosarcomas of the skull base with carbon ions. Int J Radiat Oncol Biol Phys 53(1):36–42. https://doi.org/10.1016/s0360-3016(01)02827-9
Averbeck NB, Topsch J, Scholz M, Kraft-Weyrather W, Durante M, Taucher-Scholz G (2016) Efficient rejoining of DNA double-strand breaks despite increased cell-killing effectiveness following spread-out Bragg peak carbon-ion irradiation. Front Oncol 6:28–28. https://doi.org/10.3389/fonc.2016.00028
Dangor J (2019) Mayo Clinic, Hitachi to build first, next generation, carbon ion therapy treatment facility in North America. The Mayo Clinic. Accessed December 2019. https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-hitachi-to-build-first-next-generation-carbon-ion-therapy-treatment-facility-in-north-america/
Combs SE, Ellerbrock M, Haberer T, Habermehl D, Hoess A, Jäkel O, Jensen A, Klemm S, Münter M, Naumann J, Nikoghosyan A, Oertel S, Parodi K, Rieken S, Debus J (2010) Heidelberg ion therapy center (HIT): initial clinical experience in the first 80 patients. Acta Oncol 49(7):1132–1140. https://doi.org/10.3109/0284186X.2010.498432
Guan X, Gao J, Hu J, Hu W, Yang J, Qiu X, Hu C, Kong L, Lu JJ (2019) The preliminary results of proton and carbon ion therapy for chordoma and chondrosarcoma of the skull base and cervical spine. Radiat Oncol 14(1):206–206. https://doi.org/10.1186/s13014-019-1407-9
Mizoe J-E, Hasegawa A, Takagi R, Bessho H, Onda T, Tsujii H (2009) Carbon ion radiotherapy for skull base chordoma. Skull Base 19(3):219–224. https://doi.org/10.1055/s-0028-1114295
Takagi M, Demizu Y, Nagano F, Terashima K, Fujii O, Jin D, Mima M, Niwa Y, Katsui K, Suga M, Yamashita T, Akagi T, Sakata K-I, Fuwa N, Okimoto T (2018) Treatment outcomes of proton or carbon ion therapy for skull base chordoma: a retrospective study. Radiat Oncol 13(1):232–232. https://doi.org/10.1186/s13014-018-1173-0
Moher D, Liberati A, Tetzlaff J, Althman D (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PloS Med 6(7):e1000097
U.S. Department of Human Health Services (2010) Common Terminology Criteria for Adverse Events (CTCAE) v4.0. National Institutes of Health. https://www.eortc.be/services/doc/ctc/ctcae_4.03_2010-06-14_quickreference_5x7.pdf. Accessed Accessed March 2019
Freeman MF, Tukey JW (1950) Transformations related to the angular and the square root. Ann Math Statist 21(4):607–611. https://doi.org/10.1214/aoms/1177729756
Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. Br Med J 327(7414):557–560
Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O'Connell D, Oxman AD, Phillips B, Schunemann HJ, Edejer T, Varonen H, Vist GE, Williams JW Jr, Zaza S (2004) Grading quality of evidence and strength of recommendations. BMJ (Clin Res ed) 328(7454):1490. https://doi.org/10.1136/bmj.328.7454.1490
Wells G, Shea B, O’connell D, Peterson J, Welch V, Losos M, Tugwell P (2016) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute, Ottawa. 2009. Available in March
Murad MH, Sultan S, Haffar S, Bazerbachi F (2018) Methodological quality and synthesis of case series and case reports. BMJ Evid-Based Med 23(2):60–63. https://doi.org/10.1136/bmjebm-2017-110853
Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ (Clin Res ed) 315(7109):629–634
Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56(2):455–463
Mattke M, Vogt K, Bougatf N, Welzel T, Oelmann-Avendano J, Hauswald H, Jensen A, Ellerbrock M, Jäkel O, Haberer T, Herfarth K, Debus J, Uhl M (2018) High control rates of proton- and carbon-ion-beam treatment with intensity-modulated active raster scanning in 101 patients with skull base chondrosarcoma at the Heidelberg Ion Beam Therapy Center. Cancer 124(9):2036–2044. https://doi.org/10.1002/cncr.31298
Uhl M, Mattke M, Welzel T, Oelmann J, Habl G, Jensen AD, Ellerbrock M, Haberer T, Herfarth KK, Debus J (2014) High control rate in patients with chondrosarcoma of the skull base after carbon ion therapy: first report of long-term results. Cancer 120(10):1579–1585. https://doi.org/10.1002/cncr.28606
Uhl M, Mattke M, Welzel T, Roeder F, Oelmann J, Habl G, Jensen A, Ellerbrock M, Jäkel O, Haberer T, Herfarth K, Debus J (2014) Highly effective treatment of skull base chordoma with carbon ion irradiation using a raster scan technique in 155 patients: first long-term results. Cancer 120(21):3410–3417. https://doi.org/10.1002/cncr.28877
Rieken S, Habermehl D, Nikoghosyan A, Jensen A, Haberer T, Jäkel O, Münter MW, Welzel T, Debus J, Combs SE (2011) Assessment of early toxicity and response in patients treated with proton and carbon ion therapy at the Heidelberg ion therapy center using the raster scanning technique. Int J Radiat Oncol Biol Phys 81(5):e793–e801. https://doi.org/10.1016/j.ijrobp.2010.12.018
Schulz-Ertner D, Karger CP, Feuerhake A, Nikoghosyan A, Combs SE, Jäkel O, Edler L, Scholz M, Debus J (2007) Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas. Int J Radiat Oncol Biol Phys 68(2):449–457. https://doi.org/10.1016/j.ijrobp.2006.12.059
Schulz-Ertner D, Nikoghosyan A, Hof H, Didinger B, Combs SE, Jäkel O, Karger CP, Edler L, Debus J (2007) Carbon ion radiotherapy of skull base chondrosarcomas. Int J Radiat Oncol Biol Phys 67(1):171–177. https://doi.org/10.1016/j.ijrobp.2006.08.027
Combs SE, Nikoghosyan A, Jaekel O, Karger CP, Haberer T, Münter MW, Huber PE, Debus J, Schulz-Ertner D (2009) Carbon ion radiotherapy for pediatric patients and young adults treated for tumors of the skull base. Cancer 115(6):1348–1355. https://doi.org/10.1002/cncr.24153
Combs SE, Kalbe A, Nikoghosyan A, Ackermann B, Jäkel O, Haberer T, Debus J (2011) Carbon ion radiotherapy performed as re-irradiation using active beam delivery in patients with tumors of the brain, skull base and sacral region. Radiother Oncol 98(1):63–67. https://doi.org/10.1016/j.radonc.2010.10.010
Schulz-Ertner D, Nikoghosyan A, Didinger B, Karger CP, Jäkel O, Wannenmacher M, Debus J (2003) Treatment planning intercomparison for spinal chordomas using intensity-modulated photon radiation therapy (IMRT) and carbon ions. Phys Med Biol 48(16):2617–2631. https://doi.org/10.1088/0031-9155/48/16/304
Weber DC, Murray F, Combescure C, Calugaru V, Alapetite C, Albertini F, Bolle S, Goudjil F, Pica A, Walser M, Mammar H, Bachtiary B, Lomax T, Noël G, Dendale R, Feuvret L (2018) Long term outcome of skull-base chondrosarcoma patients treated with high-dose proton therapy with or without conventional radiation therapy. Radiother Oncol 129(3):520–526. https://doi.org/10.1016/j.radonc.2018.06.040
Fung V, Calugaru V, Bolle S, Mammar H, Alapetite C, Maingon P, De Marzi L, Froelich S, Habrand J-L, Dendale R, Noël G, Feuvret L (2018) Proton beam therapy for skull base chordomas in 106 patients: a dose adaptive radiation protocol. Radiother Oncol 128(2):198–202. https://doi.org/10.1016/j.radonc.2017.12.017
Jägersberg M, El Rahal A, Dammann P, Merkler D, Weber DC, Schaller K (2017) Clival chordoma: a single-centre outcome analysis. Acta Neurochir (Wien) 159(10):1815–1823. https://doi.org/10.1007/s00701-017-3163-7
Weber DC, Rutz HP, Pedroni ES, Bolsi A, Timmermann B, Verwey J, Lomax AJ, Goitein G (2005) Results of spot-scanning proton radiation therapy for chordoma and chondrosarcoma of the skull base: the Paul Scherrer Institut experience. Int J Radiat Oncol Biol Phys 63(2):401–409. https://doi.org/10.1016/j.ijrobp.2005.02.023
Ares C, Hug EB, Lomax AJ, Bolsi A, Timmermann B, Rutz HP, Schuller JC, Pedroni E, Goitein G (2009) Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report. Int J Radiat Oncol Biol Phys 75(4):1111–1118. https://doi.org/10.1016/j.ijrobp.2008.12.055
Munzenrider JE, Liebsch NJ (1999) Proton therapy for tumors of the skull base. Strahlenther Onkol 175(Suppl 2):57–63. https://doi.org/10.1007/bf03038890
Almefty K, Pravdenkova S, Colli BO, Al-Mefty O, Gokden M (2007) Chordoma and chondrosarcoma: similar, but quite different, skull base tumors. Cancer 110(11):2457–2467. https://doi.org/10.1002/cncr.23073
Imai R, Kamada T, Araki N, Working Group for B, Soft Tissue S (2016) Carbon ion radiation therapy for unresectable sacral chordoma: an analysis of 188 cases. Int J Radiat Oncol Biol Phys 95(1):322–327. https://doi.org/10.1016/j.ijrobp.2016.02.012
Anzai M, Yamamoto N, Hayashi K, Nakajima M, Nomoto A, Ogawa K, Tsuji H (2020) Safety and efficacy of carbon-ion radiotherapy alone for stage III non-small cell lung cancer. Anticancer Res 40(1):379–386. https://doi.org/10.21873/anticanres.13963
Peeters A, Grutters JPC, Pijls-Johannesma M, Reimoser S, De Ruysscher D, Severens JL, Joore MA, Lambin P (2010) How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. Radiother Oncol 95(1):45–53. https://doi.org/10.1016/j.radonc.2009.12.002
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors report no funding sources or conflict of interest concerning the materials or methods used in this study or the findings specified in this study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Lu, V.M., O’Connor, K.P., Mahajan, A. et al. Carbon ion radiotherapy for skull base chordomas and chondrosarcomas: a systematic review and meta-analysis of local control, survival, and toxicity outcomes. J Neurooncol 147, 503–513 (2020). https://doi.org/10.1007/s11060-020-03464-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-020-03464-1